Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 801–900 of 1,004
Kuzmina, A., Korovin, D., Cohen-Lass, I., Atari, N., Ottolenghi, A., Hu, P., Mandelboim, M., Rosental, B., Rosenberg, E., Diaz‐Griffero, F., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16750 · Cited by 8
Luan, N., Wang, Y., Cao, H., Lin, K., & Liu, C. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27637 · Cited by 8
Targeted Delivery of mRNA to the Heart via Extracellular Vesicles or Lipid Nanoparticles
Nawaz, M., Tangruksa, B., Heydarkhan‐Hagvall, S., Kohl, F., González‐King, H., Jing, Y., Payandeh, Z., Reyahi, A., Jennbacken, K., Wiseman, J., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70324 · Cited by 8
Harnessing RNA molecules for therapy: advances in design, delivery, and clinical development
Zou, J., He, X., Li, Z., Song, B., Xing, X., Yu, J., & He, W. (2025) · Targetome · doi:10.48130/targetome-0025-0003 · Cited by 8
Bánki, Z., Seekircher, L., Falkensammer, B., Bante, D., Schäfer, H., Harthaller, T., Kimpel, J., Willeit, P., von Laer, D., & Borena, W. (2022) · Viruses · doi:10.3390/v14081642 · Cited by 8
“Despite the observed gradual decline in the efficacy of preventing symptomatic infections over 6 months, BNT162b2 vaccination is highly efficient in preventing severe COVID-19 [1].”
BackgroundResultInfluentialLeung, H. T., Gong, W. J., Sit, S. M.-M., Lai, A. Y. K., Ho, S. Y., Wang, M. P., & Lam, T. H. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1012146 · Cited by 7
“As mass vaccination programme is made available, more and more people are protected against serious consequences of COVID-19 (28, 29).”
BackgroundEffect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models
Zirkenbach, V. A., Ignatz, R. M., Öttl, R., Cehreli, Z., Stroikova, V., Kaya, M., Lehmann, L., Preusch, M. R., Frey, N., & Kaya, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055011 · Cited by 7
SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison
Alcorta-Núñez, F., Pérez-Ibave, D. C., Burciaga-Flores, C. H., Garza, M., González-Escamilla, M., Rodríguez-Niño, P., González-Guerrero, J. F., Alcorta-Garza, A., Vidal-Gutiérrez, Ó., Ramirez‐Correa, G. A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13061194 · Cited by 8
Ishikawa, K., Nascimento, M., Asano, M., Hirata, H., Itoh, Y., Kelly, E. J., Matsui, A., Olsson, U., Shoemaker, K., & Green, J. A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.015 · Cited by 7
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Chen, Z., Liu, Z., Feng, Y., Shi, A., Wu, L., Sang, Y., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1259788 · Cited by 8
Efficacy and effectiveness of COVID-19 vaccines in Africa: A systematic review
Raji, T., Fallah, M. P., Dereje, N., Kakooza, F., Ndembi, N., Abdulaziz, M., Aragaw, M., Kaseya, J., & Ngongo, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0306309 · Cited by 7
Stäb, S., Pearce, N. M., Tronrud, D. E., Ginn, H. M., Fadda, E., Santoni, G., & Thorn, A. (2024) · Crystallography Reviews · doi:10.1080/0889311x.2024.2363756 · Cited by 7
A nucleoside-modified mRNA vaccine prevents enterovirus A71 infection in mouse model
Chi, F., Zhang, X., Zhang, D., Zhu, A., Zhuang, Z., Zhang, Z., Zhang, Z., Quan, C., Nie, K., Li, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1535758 · Cited by 8
Hodgson, D., Liu, Y., Carolan, L. A., Mahanty, S., Subbarao, K., Sullivan, S. G., Fox, A., & Kucharski, A. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1487066 · Cited by 7
Vaccines for preventing infections in adults with solid tumours
Hirsch, C., Zorger, A.-M., Baumann, M., Park, Y. S., Bröckelmann, P. J., Mellinghoff, S. C., Monsef, I., Skoetz, N., & Kreuzberger, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015551.pub2 · Cited by 7
Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2
Dionne, K., Tauzin, A., Bélanger, É., Desfossés, Y., Benlarbi, M., Niu, L., Beaudoin-Bussières, G., Medjahed, H., Bourassa, C., Perreault, J., et al. (2025) · Viruses · doi:10.3390/v17050666 · Cited by 7
Nazar, W., Romantowski, J., Nazar, G., Niedoszytko, M., Braun-Dullaeus, R. C., & Daniłowicz‐Szymanowicz, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-03428-3 · Cited by 7
In Silico Study of Ionizable Lipid Nanoparticles Using the SPICA Force Field
Singh, A. P., Tanaka, H., Miyazaki, Y., Nagano, S., & Shinoda, W. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c00498 · Cited by 7
Praktischer Umgang mit allergischen Reaktionen auf COVID-19-Impfstoffe
Klimek, L., Bergmann, K., Brehler, R., Pfützner, W., Worm, M., Hartmann, K., Jakob, T., Novak, N., Ring, J., Hamelmann, E. H., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4773-1 · Cited by 7
PAVING THE WAY TOWARDS PRECISION VACCINOLOGY: THE PARADIGM OF MYOCARDITIS AFTER COVID-19 VACCINATION
Lagousi, T., Papadatou, I., Strempas, P., Chatzikalil, E., & Spoulou, V. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac396 · Cited by 7
“A number 31 of different vaccines against COVID-19 approved for emergency use in less than a year 32 completely changed the course of the pandemic and significantly reduced COVID-19 related 33 morbidity and mortality worldwide among individuals of different ages, highlighting the 34 success of current vaccinology [12-…”
BackgroundLi, J., Hui, A., Zhang, X., Ge, L., Qiu, Y., Tang, R., Ye, H., Wang, X., Lin, M., Zhu, Z., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02206-1 · Cited by 8
“BNT162b2 has been shown to maintain a favorable safety profile up to 6 months post full vaccination [16].”
BackgroundSelf-citationEl-Menyar, A. A., Khan, N. A., Mekkodathil, A. A., Rizoli, S. B., Consunji, R. J., Elmenyar, E., Galwankar, S. C., & Al-Thani, H. A. S. (2022) · Medicine · doi:10.1097/md.0000000000030609 · Cited by 7
“A placebo-controlled, observer-blinded, multinational, pivotal efficacy trial in the general population (n = 46,429) reported that systemic events were mostly mild to moderate in severity; however, occasional severe events occurred.[23] These 2 studies aimed to establish the waning of immunity with 2 doses of the BNT1…”
BackgroundInfluentialLambìase, A., Sacchetti, M., Mallone, F., Tirassa, P., Greco, A., Angeloni, A., & Polimeni, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102430 · Cited by 7
“The evidence of decline in vaccine-induced immunity over time led to the booster dose (BD) vaccination, which has been shown to be effective in inducing the recovery of systemic immunity, but its effect on the mucosal immune reaction has not yet been investigated [2,3].”
BackgroundCOVID-19 Vaccination: Sociopolitical and Economic Impact in the United States
Jeon, S., Lee, Y.-F. L., & Koumi, K. (2022) · Epidemiologia · doi:10.3390/epidemiologia3040038 · Cited by 7
“, shortness of breath or chest pain) were low and comparable to other vaccines and placebo groups (also see [18]).”
ResultRane, M. S., Robertson, M. M., Kulkarni, S., Frogel, D., Gainus, C., & Nash, D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.039 · Cited by 8
“All recommended vaccines have shown high efficacy against severe disease and mortality in clinical trials against the alpha and delta variants of SARS-CoV-2 virus [3,5,6,8].”
Lai, Y.-H., Chen, H.-Y., Chiu, H., Kang, Y., & Wong, S. (2022) · Vaccines · doi:10.3390/vaccines10122174 · Cited by 8
“Two BNT162b2 [5,22] and two mRNA-1273 [23,24] studies reported efficacy and safety issues among the same participants.”
BackgroundCalzetta, L., Chetta, A. A., Aiello, M., Frizzelli, A., Ora, J., Melis, E., Facciolo, F., Ippoliti, L., Magrini, A., & Rogliani, P. (2023) · Vaccines · doi:10.3390/vaccines11020282 · Cited by 7
“From a clinical point of view, it is not possible to check if BNT162b2 may really elicit a greater risk of bronchospasm compared to a placebo because, unexpectedly, the key sponsored phase 3 RCT on BNT162b2 (NCT04368728, NCT04713553, NCT04816669), although already completed and/or published in MEDLINE, reported no res…”
BackgroundRubenstein, B. L., Amiel, P. J., Ternier, A., Helmy, H. L., Lim, S., Chokshi, D. A., & Zucker, J. R. (2023) · Health Affairs · doi:10.1377/hlthaff.2022.00809 · Cited by 9
Tamming, L. A., Duque, D., Bavananthasivam, J., Tran, A., Lansdell, C., Frahm, G. E., Wu, J., Fekete, E. E. F., Creskey, M., Raman, S. N. T., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101325 · Cited by 7
Quantification of Vaccine Waning as a Challenge Effect
Janvin, M., & Stensrud, M. J. (2024) · Journal of the American Statistical Association · doi:10.1080/01621459.2024.2408776 · Cited by 12
“To distinguish between these two explanations, we conducted inference on (1) using publicly available summary data from Thomas et al. (2021), reported in Table 2.”
InfluentialSzebeni, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040450 · Cited by 9
“The statement on safety was reinforced in an international 6-month efficacy and safety study involving 21,926 recipients of Comirnaty and an equal number of participants who received placebo [21].”
InfluentialFahrbach, K. R., Cichewicz, A. B., Chu, H., Fusco, M. D., Burnett, H. F., Volkman, H. R., Akin‐Fajiye, M., Mendoza, C. F., & Cappelleri, J. C. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2505754 · Cited by 7
“The base-case results showed that, among elderly populations older than 60 years of age, both vaccines were effective in preventing hospitalizations, with BNT162b2 having a statistically significantly improved VE compared to mRNA-1273 (26% [95% CrI: 5, 40]).”
InfluentialJang, W., Kim, B., Kim, E. S., Song, K., Moon, S. M., Lee, M. J., Park, J. Y., Kim, J., Shin, M. J., Lee, H., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e343 · Cited by 7
Magalis, B. R., Rich, S. N., Tagliamonte, M. S., Mavian, C. N., Cash, M. N., Riva, A., Marini, S., Amador, D. M., Zhang, Y., Shapiro, J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac197 · Cited by 7
“Although vaccination continues to provide excellent protection against hospitalization and death, a gradual decline in vaccine efficacy against infection was observed in 2021 [20].”
Brosh‐Nissimov, T., Maor, ., Elbaz, M., Lipman‐Arens, S., Weil‐Weiner, Y., Hussein, K., Orenbuch‐Harroch, E., Cohen, R., Zimhony, O., Chazan, B., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.20.2101026 · Cited by 7
Kang, J., Lee, J., Huh, K. H., Joo, D. J., Lee, J. G., Kim, H. R., Kim, H. Y., Lee, M., Jung, I., Kim, M. Y., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004241 · Cited by 7
Mahalingam, K., Surbhi, Balaji, A., Ganesh, R., Daniel, R., Aggarwal, R., Soni, K., Singh, A., Khanna, P., Gupta, V., et al. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1937_21 · Cited by 5
Siangphoe, U., Baden, L. R., Sahly, H. M. E., Essink, B. J., Ali, K., Berman, G., Tomassini, J. E., Deng, W., Pajón, R., McPhee, R. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac780 · Cited by 7
Episomes and Transposases—Utilities to Maintain Transgene Expression from Nonviral Vectors
Kreppel, F., & Hagedorn, C. (2022) · Genes · doi:10.3390/genes13101872 · Cited by 8
“It has been used in slightly different forms as the delivery vehicle for mRNA-based vaccines against COVID-19 [159,160].”
BackgroundWallace, M., Collins, J., Moline, H. L., Plumb, I., Godfrey, M., Morgan, R. L., Campos-Outcalt, D., Oliver, S. E., Dooling, K., & Gargano, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278624 · Cited by 6
Short-Lived Antibody-Mediated Saliva Immunity against SARS-CoV-2 after Vaccination
Madsen, J. R., Holm, B. E., Pérez‐Alós, L., Bayarri‐Olmos, R., Rosbjerg, A., Fogh, K., Pries‐Heje, M. M., Møller, D. L., Hansen, C. B., Heftdal, L. D., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04947-22 · Cited by 7
“So far, they have proven to be safe and highly efficacious in preventing severe disease and hospitalization (6).”
BackgroundVaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H., Aviszus, K., Zelarney, P. T., Liao, S., Gerber, A. N., Make, B. J., Wechsler, M. E., Marrack, P., & Reinhardt, R. L. (2023) · ERJ Open Research · doi:10.1183/23120541.00400-2023 · Cited by 7
“Underlying their potential importance, the relative expansion of SARS-CoV-2-specific CD4 + and CD8 + T-cells associates with COVID-19 disease severity, and T-cell memory appears more durable than serum antibody titres [18, 25, 35, 38, 39].”
BackgroundInfluentialAdenovirus-vectored PDCoV vaccines induce potent humoral and cellular immune responses in mice
Miao, X., Zhang, L., Zhou, P., Yu, R., Zhang, Z., Wang, C., Guo, H., Wang, Y., Li, P., & Liu, X. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.053 · Cited by 7
Encouraging COVID-19 vaccination by focusing on anticipated affect: A scoping review
Okuhara, T., Shirabe, R., Kagawa, Y., Okada, H., & Kiuchi, T. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22655 · Cited by 7
“Additionally, regular multiple doses are recommended because the effect of the COVID-19 vaccines declines over a period of several months [7,8].”
BackgroundClothier, H. J., Shetty, A. N., Mesfin, Y. M., Mackie, M., Pearce, C. M., & Buttery, J. P. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.025 · Cited by 7
COVID-19 knowledge deconstruction and retrieval: an intelligent bibliometric solution
Wu, M., Zhang, Y., Markley, M., Cassidy, C., Newman, N. C., & Porter, A. L. (2023) · Scientometrics · doi:10.1007/s11192-023-04747-w · Cited by 7
“…addition to the massive numbers of basic medicine and clinical trial studies around the safety and efficacy of those vaccines (Polack et al., 2020; Thomas et al., 2021; Xia et al., 2020), the rollout of vaccines also triggers researchers’ concerns about the social implications, including the…”
BackgroundDíaz-Dinamarca, D. A., Díaz, P., Barra, G. N., Puentes, R., Arata, L., Grossolli, J., Riveros-Rodriguez, B., Ardiles, L., Santelises, J., Vásquez-Sáez, V., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229045 · Cited by 7
“Studies have indicated that the antibody responses elicited by CoronaVac and BNT162b2 have decreased after 6 months, possibly contributing to an increase in breakthrough infections (13, 35, 36).”
BackgroundSalvagno, G. L., Henry, B. M., Pighi, L., NITTO, S. D., Gianfilippi, G., & Lippi, G. (2021) · Research Square · doi:10.21203/rs.3.rs-1063499/v1 · Cited by 7
“against SARS-CoV-2 infection and the risk of developing symptomatic or severe COVID-19 illness appears to be progressively waning, thus resulting in a constantly increasing risk of SARS-CoV-2 breakthrough infections, as demonstrated by recent studies [3,4].”
ResultNguyen, T. P., Đỗ, Q., Lan, P. T., Anh, Đ. Đ., Khong, H., Nguyễn, T. V., Hoang, L. V., Dinh, D. V., Pham, H. N., Chu, M. V., et al. (2022) · medRxiv · doi:10.1101/2022.03.22.22272739 · Cited by 7
Emani, V. R., Pallipuram, V. K., Goswami, K. K., Maddula, K. R., Reddy, R., Nakka, A. S., Panga, S., Reddy, N. K., Reddy, N. K., Nandanoor, D., et al. (2022) · medRxiv · doi:10.1101/2022.06.28.22276926 · Cited by 7
Yamagata, H. M., Padilla, M. S., Hamilton, A. G., Swingle, K. L., Thatte, A. S., Ricciardi, A. S., Agrawal, A., Fitzgerald, E., Poirier, A. J., Geisler, H. C., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c00080 · Cited by 7
Zhang, B., Zhang, H., Wang, Z., Cao, H., Zhang, N., Dai, Z., Liang, X., Peng, Y., Wen, J., Zhang, X., et al. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14500 · Cited by 6
The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities
Shani, M., Hermesh, I., Feldhamer, I., Reges, O., Lavie, G., Arbel, R., & Sagy, Y. W. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.097 · Cited by 6
COVID-19 Vaccination Recommendations for 2024–2025 in Korea
Park, W. B., Hwang, Y. H., Kwon, K. T., Noh, J. Y., Park, S. H., Song, J. Y., Choo, E. J., Choi, M. J., Choi, J. Y., Heo, J. Y., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2024.0142 · Cited by 6
“However, the immunity acquired through infection or vaccination is known to diminish over time [9, 10].”
Pharmaceutical product recall and educated hesitancy towards new drugs and novel vaccines
Rhodes, P., & Parry, P. I. (2024) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479241292008 · Cited by 7
Xu, Y., Qi, S., Zhang, G., Liu, D., Xu, D., Qin, T., Cheng, Q., Kang, H. C., Hu, B., & Huang, Z. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1280 · Cited by 7
“Among these, m 1 ψ has been proven effective in mRNA therapeutics, which were first successfully used as vaccines against the COVID-19 epidemic, saving tens of millions of lives ( 12 ,13 ).”
Complement is primarily activated in the lung in a mouse model of severe COVID-19
Szachowicz, P. J., Wohlford-Lenane, C., Donelson, C. J. H., Ghimire, S., Thurman, A. L., Xue, B., Boly, T. J., Verma, A., MašinoviĆ, L., Bermick, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111930 · Cited by 6
mRNA vaccines for prostate cancer: A novel promising immunotherapy
Tang, Y., Yi, X., & Ai, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189333 · Cited by 6
Deichmann, J., Barda, N., Canetti, M., Peretz, Y., Weiss-Ottolenghi, Y., Lustig, Y., Regev‐Yochay, G., & Lipsitch, M. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013192 · Cited by 6
Li, X., Chen, L., Yu, H., Xiong, L., Song, W., Li, X., Liu, G., Li, W., & Tang, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01618 · Cited by 6
Colston, K. J., Monsalve, S. C., & Schneebeli, S. T. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00348 · Cited by 7
Vignals, C., Dick, D. W., Thiébaut, R., Wittkop, L., Prague, M., & Heffernan, J. M. (2021) · COVID · doi:10.3390/covid1020041 · Cited by 7
Cutaneous adverse reactions to coronavirus vaccines: A Saudi nationwide study
Bukhari, A., Almutlq, M. M., Dakhil, A. A. B., Alhetheli, G. I., Alfouzan, S., Alqahtani, M. A., Aljalfan, A. A. N., Almutawa, M. A., Alsubaie, F. S., & Madani, A. N. (2022) · Dermatologic Therapy · doi:10.1111/dth.15452 · Cited by 6
“trials of the Pfizer–BioNTech COVID-19 vaccine began in April of 2020; by November of 2020, the vaccine entered Phase III clinical trials.(3) Studies for the Oxford–AstraZeneca COVID-19 vaccine were carried out in 2020, and on December 30, 2020, the vaccine was first approved for use in the UK vaccination program.”
BackgroundMethodHow Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
Pons, S., Uhel, F., Frapy, E., Sérémé, Y., Zafrani, L., Aschard, H., & Skurnik, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10477-y · Cited by 6
One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
Wand, O., Breslavsky, A., Bar‐Shai, A., Levy, C., Maayan, S. L., Rimler, A., Zwahra, M., Cohen‐Hagai, K., Harish, A., Zacks, N., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.12.042 · Cited by 7
“Concerns regarding further decline of immunity, concomitant with a surge in COVID-19 cases caused by the highly infectious B.1.1529 (Omicron) variant worldwide, have led to the authorization of a fourth vaccine dose by the Israeli Ministry of Health, initially for high-risk and elderly individuals and healthcare worke…”
InfluentialCOVID-19 Vaccines—All You Want to Know
Shishido, A. A., Barnes, A. H., Narayanan, S., & Chua, J. V. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1759779 · Cited by 6
Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19
Liu, Z., Han, Z., Jin, X., An, J., Kim, J., Chen, W., Kim, J. S., Zheng, J., & Deng, J. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.010 · Cited by 6
Kawano, H., Umeda, M., Okano, S., & Kudo, T. (2023) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytad102 · Cited by 6
Valore, L., Junker, T., Heilmann, E., Zuern, C. S., Streif, M., Drexler, B., Arranto, C., Halter, J. P., & Berger, C. T. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1135848 · Cited by 7
Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context
Rhodes, P., & Parry, P. I. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155030 · Cited by 6
Elias, L. B., Jaber, A., Manzano, M., Leekoff, M. L., Sylvester, A., & Tremblay, M. A. (2023) · Vaccines · doi:10.3390/vaccines11121855 · Cited by 6
“In late 2020, two mRNA vaccines against SARS-CoV-2 were authorized for prevention of COVID-19 and have proven to be effective for the prevention of morbidity and death from COVID-19 [2,3].”
BackgroundErfanpoor, S., Banihashemi, S. R., Mokhberalsafa, L., Kalantari, S., Es‐haghi, A., Noofeli, M., Mokarram, A. R., Sadeghi, F., Hajimoradi, M., Razaz, S. H., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03295-1 · Cited by 6
COVID-19 vaccine: the gender disparity
Corda, V., Murgia, F., & Monni, G. (2021) · Journal of Perinatal Medicine · doi:10.1515/jpm-2021-0246 · Cited by 6
Lopez, M. V., Vinzón, S. E., Cafferata, E. G. A., Núñez, F. J., Soto, A. S., Sánchez‐Lamas, M., Afonso, M. J., Aguilar-Cortes, D. C., Ríos, G. D., Maricato, J. T., et al. (2021) · Vaccines · doi:10.3390/vaccines9101106 · Cited by 6
Putra, W. F. (2022) · Jurnal Kedokteran Meditek · doi:10.36452/jkdoktmeditek.v28i1.2243 · Cited by 10
Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm
Abusalah, M. A. H., Khalifa, M., Al-Hatamleh, M. A. I., Jarrar, M., Mohamud, R., & Yean, C. Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030386 · Cited by 6
Zhou, B., Song, S., Guo, H., Zhou, X., Fan, Q., Liu, W., Cheng, L., Ge, X., Ju, B., & Zhang, Z. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27811 · Cited by 6
“the waning of the titers in neutralizing antibodies (nAbs) and the emerging variants of SARS‐CoV‐2, the protective efficacies of various vaccines were significantly decreased.(2,3) Although several studies”
Poh, X. Y., Lee, I. R., Lim, C., Teo, J., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Kline, S., Ng, L. F. P., et al. (2022) · Trials · doi:10.1186/s13063-022-06345-2 · Cited by 6
“9) from 4 months to the data cut-off [2].”
BackgroundTanır, F., Mete, B., Demırhındı, H., Kara, E., Nazlıcan, E., Dağlıoğlu, G., Kibar, F., Çetiner, S., & Kanat, C. (2022) · Vaccines · doi:10.3390/vaccines10081177 · Cited by 6
“(in a longer follow-up of phase 2–3 randomized trial of BNT) [13] a 96–84% reduction in vaccine efficacy between month 4 and 7.”
BackgroundObstetric services in the UK during the COVID-19 pandemic: A national survey
O’Carroll, J., Zucco, L., Warwick, E., Arbane, G., Moonesinghe, R., El‐Boghdadly, K., Guo, N., Carvalho, B., & Sultan, P. (2022) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2022.101137 · Cited by 7
Zagouri, F., Papatheodoridi, A. M., Liontos, M., Briasoulis, Α., Sklirou, A. D., Skafida, E., Fiste, O., Markellos, C., Andrikopoulou, Α., Koutsoukos, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10091474 · Cited by 6
“As has been described before, NAb titers increase after the 2nd dose of the vaccine but tend to decline over time in both groups [1,19,20].”
BackgroundLessons from a large-scale COVID-19 vaccine trial
Mahla, R. S., & Dustin, L. B. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163202 · Cited by 6
Li, J., Ge, M., Dai, S., Song, Q., Liu, W., Wang, Y., Xu, W., & Ma, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030238 · Cited by 6
“7% from 4 months-an average decline of approximately 6% every 2 months (18).”
BackgroundGonzález‐López, T. J., Bárez, A., Bernardo, Á., Bernat, S., Canaro, M., Entrena‐Ureña, L., Fernández‐Fuertes, F., de Castro, J. M. G., Jiménez‐Bárcenas, R., Pascual, C., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00745-2 · Cited by 6
Petrović, V., Vuković, V., Patić, A., Marković, M., & Ristić, M. (2022) · Vaccines · doi:10.3390/vaccines11010056 · Cited by 7
“Several studies investigated the immune response after application of the BNT162b2 vaccine as one of the widely administered SARS-CoV-2 vaccines worldwide, and even though high efficacy was announced after two doses of above 90% up to 6 months [49], an important long-term decline in Ab titers/levels was reported acros…”
BackgroundEvaluation of Anti-SARS-CoV-2 IgA Response in Tears of Vaccinated COVID-19 Subjects
Soffritti, I., D’Accolti, M., Gallenga, C. E., GIORGIO, R. D., Guarino, M., Maritati, M., Bini, F., Mazziga, E., Contini, C., & Caselli, E. (2023) · Viruses · doi:10.3390/v15020399 · Cited by 6
A free boundary problem-in time-for the spread of Covid-19
Luckhaus, S., & Stevens, A. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01881-0 · Cited by 7
“McKendrick models in epidemiology are now often called age-structured population models and treated in the framework of delay-differential-equations, see (Hale 1977; Thieme 2003; Rass and Radcliffe 2003; Diekmann et al. 2012).”
MethodMíguez, H. M., García, I. M., Gómez, M. O., Merino, I. M. G., Cano, E. L., & de la Torre, A. (2023) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2023.02.009 · Cited by 6
Bannister, W. P., Raben, D., Valentiner‐Branth, P., Tolstrup, M., Larsen, L., Tarp, B., Iversen, M. B., Søgaard, O. S., Ostrowski, S. R., Stærke, N. B., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad248 · Cited by 6
Alsaeedi, F. A., Gharib, A. F., Hassan, A., Alrehaili, A. A., Althubiti, R. M., Alharthi, F. M., Al-Otaibi, S. S., Thomali, A. M. A., Bakhuraysah, M. M., Alsalmi, O. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22291 · Cited by 6
“It is worth noting that while COVID-19 vaccinations are very effective at stopping severe illness and hospitalization, they do not offer 100 % protection against infection [18].”
BackgroundCell immunity to SARS-CoV-2 after natural infection and/or different vaccination regimens
Culebras, E., Martínez, M., Novella, C., León, J. M., Marcos, E., Delgado‐Iribarren, A., & Ríos, E. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1370859 · Cited by 6
“Vaccine-induced immunity remains effective at preventing severe disease, hospitalization, and death, even at later time points when antibody levels may have declined (Grif fi n et al., 2021; Thomas et al., 2021).”
BackgroundInterstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran
Oda, N., Mitani, R., Takata, I., & Kataoka, M. (2022) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2022.101618 · Cited by 6
“Tozinameran, a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine, has a favorable safety profile and is highly efficacious in preventing COVID-19 [1].”
Córdova, E., Lespada, M. I., Cecchini, D. M., Nieto, F., Palonsky, S., Badran, M., Bernasconi, S. V., Bacelar, B., Morganti, L., Garibaldi, F., et al. (2022) · Vacunas · doi:10.1016/j.vacun.2022.01.008 · Cited by 6
SARS-CoV-2 surveillance and outbreak response on an urban American college campus
Towers, S. A., Gemechu, N., Nagaraj, N. C., Landry, M., Beane, P., Sardon, G. A., Weiss, E. C., Liu, C. M., Park, D. E., Aziz, M., et al. (2022) · Journal of American College Health · doi:10.1080/07448481.2022.2034834 · Cited by 6
“17 While the low test positivity rate seen during the study period was likely achieved in part by the reduced capacity in residential housing and classrooms, we were able to interrupt chains of transmission in several instances given that much of the transmission was in off-campus settings and that…”
BackgroundPalacka, P., Polanová, M., Svobodová, A., Zigmond, J., Zanchetta, K., Gombarova, V., Vulganova, M., Slopovský, J., Obertová, J., Drgoňa, Ľ., et al. (2022) · Vaccines · doi:10.3390/vaccines10040558 · Cited by 6
“The high effectiveness of BNT162b2 is consistent with 6 months of follow-up among the participants aged 16 years and older in a large placebo-controlled phase III trial [8], in which a vaccine efficacy of 86% to 100% was seen across countries and populations of differing age, gender, ethnic group, and risk factors (su…”
BackgroundMethodScaramuzza, A. E., Cherubini, V., Schiaffini, R., Rabbone, I., The Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes, Gallo, F., Fichera, G., Arnaldi, C., Bonfanti, R., Lombardo, F., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01885-0 · Cited by 6
“05% (calculated according to a total number of patients older than 12 years in the responder centers (n = 7,511) and a minimum vaccination rate of 75% of children older than 12), in line with published data [3].”
BackgroundHamid, R., Korkmazer, B., Kızılkılıç, E. K., Arman, G. M., Özoğul, M., Kargın, O. A., Arslan, S., & Kızılkılıç, O. (2022) · Ear Nose & Throat Journal · doi:10.1177/01455613221113818 · Cited by 6
“The BNT162b2 (Pfizer-BioNTech) vaccine was the first vaccine to achieve this authorization and millions of people worldwide have been vaccinated with it.(7) Pathophysiologic mechanism of vaccine related facial palsy is unknown.”
BackgroundEvaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study
Lim, A. H., Rahman, N. A., Su, M.-O., Paraja, J., Rashid, R., Parmar, I., Dahlan, S. N., Tan, Z., Bohari, I., Peariasamy, K., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.032 · Cited by 4
“sensitive to differences in care seeking [16].”
BackgroundLi, J., Li, Z., Zhu, Y., Zhou, L., & Zhu, F. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0025 · Cited by 7
Ong, M. J. Y., Khoo, C. S., Lee, Y. X., Poongkuntran, V., Tang, C. K., Choong, Y. J., Hod, R., & Tan, H. J. (2022) · Epilepsia Open · doi:10.1002/epi4.12658 · Cited by 6
“31,36,37 The present study did not include etiology of epilepsy as a variable as the aetiologies of several participants were yet to be identified.”
Influential
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.